18 research outputs found

    ΠšΠΎΡ€Ρ€Π΅ΠΊΡ†ΠΈΡ Π΄Π²ΠΈΠ³Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΈ повСдСнчСских Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΉ Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ ΠΈ Ρ€Π΅Π°Π±ΠΈΠ»ΠΈΡ‚Π°Ρ†ΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΡˆΠΈΠ·ΠΎΡ‚ΠΈΠΏΠΈΡ‡Π΅ΡΠΊΠΈΠΌ расстройством

    Get PDF
    На основании особСнностСй Π½Π΅Π²Π΅Ρ€Π±Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ повСдСния Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΡˆΠΈΠ·ΠΎΡ‚ΠΈΠΏΠΈΡ‡Π΅ΡΠΊΠΈΠΌ расстройством Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Ρ‹ повСдСнчСскиС ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹, ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… Π² ΠΈΡ… комплСксной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ позволяСт Π΄ΠΎΠ±ΠΈΡ‚ΡŒΡΡ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»Π½ΠΎΠΉ Ρ€Π΅Π΄ΡƒΠΊΡ†ΠΈΠΈ психопатологичСской симптоматики.Behavioral methods were worked out basing of the peculiarities of nonβˆ’verbal behavior of the patients with schizotypical disorders. The use of the methods in complex therapy allows to achieve more complete reduction in psychopathological signs

    Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy

    No full text
    Item does not contain fulltextAIMS: We investigated the presence of a clinical diagnosis of hypertrophic cardiomyopathy (HCM), risk factors for sudden cardiac death (SCD), and cardiac events during follow-up in predictively tested-not known to have a clinical diagnosis of HCM before the DNA test-carriers of a sarcomeric gene mutation and associations with age and gender to determine the best cardiological screening strategy. METHODS AND RESULTS: One hundred and thirty-six (30%) of 446 mutation carriers were diagnosed with HCM at one or more cardiological evaluation(s). Male gender and higher age were associated with manifest disease. Incidence of newly diagnosed manifest HCM was 10% in older carriers, although numbers were small in carriers /=2 risk factors and manifest HCM) was present in 17 carriers during follow-up (2.4% per person-year). Age but not gender was associated with a high-risk status for SCD. CONCLUSION: Thirty percent of carriers had or developed manifest HCM after predictive DNA testing and risk factors for SCD were frequently present. Our data suggest that the SCD risk is low and risk stratification for SCD can be omitted in carriers without manifest disease and that frequency of cardiological evaluations can possibly be decreased in carriers between 15 and 40 years as long as hypertrophy is absent

    Towards the development of an agile marketing capability

    No full text
    This study aims to explore the key theoretical foundations for the development of an Agile Marketing Capability (AMC) framework, through the performance of an in-depth literature review on IT and dynamic marketing capabilities. Our framework enables us to (1) advance the understanding of how IT and dynamic marketing capabilities evolve into agile marketing capabilities (2) unpack the distinctive and ongoing processes and features through which the Agile Marketing capabilities are accomplished (3) define the key propositions for a new marketing capability: the Agile Marketing Capability. This work may represent a useful framework for managers and decision makers to better understand the competitive advantages which could derive from the employment of agile marketing capabilities in order to improve their skills in challenging the continuous changes in market and customers’ needs
    corecore